Kruse from Harvard Medical School. In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin ...
We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...
Tectonic recently announced its third-quarter 2024 financial results, highlighting signif Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension i ...
After hours: March 3 at 6:04:26 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback